ADMA Biologics
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $134,224 | $121,984 | $114,802 | $117,549 |
Gross Profit | 75,626 | 67,227 | 61,097 | 63,333 |
EBITDA | 51,213 | 43,989 | 37,394 | 39,536 |
EBIT | 49,190 | 41,931 | 35,425 | 37,592 |
Net Income | 36,428 | 34,219 | 26,904 | 111,896 |
Net Change In Cash | 134,224 | 121,984 | 114,802 | 117,549 |
Free Cash Flow | -1,075 | 18,717 | -24,376 | 47,459 |
Cash | 61,385 | 90,285 | 71,625 | 103,147 |
Basic Shares | 244,664 | 248,608 | 244,676 | 245,901 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $426,454 | $258,215 | $154,080 | $80,943 |
Gross Profit | 219,553 | 88,942 | 35,265 | 1,173 |
EBITDA | 147,689 | 5,120 | -39,512 | -53,095 |
EBIT | 139,644 | -3,212 | -46,625 | -58,591 |
Net Income | 197,673 | -28,239 | -65,904 | -71,648 |
Net Change In Cash | 426,454 | 258,215 | 154,080 | 80,943 |
Cost of Revenue | 35,432 | -4,832 | ||
Free Cash Flow | 110,097 | 3,819 | -73,419 | -125,880 |
Cash | 103,147 | 51,352 | 86,522 | 51,089 |
Basic Shares | 243,342 | 223,977 | 197,874 | 139,578 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | $0.15 |
2025-06-30 | $0.14 |
2025-03-31 | $0.11 |
